Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda
Background Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine. Methods and Findings We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2–19 years old in Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10). Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder was defined as a subject with a ≥4-fold increase in SBA against a target strain from each serogroup and SBA titer ≥128. For serogroup W135, 94% and 97% of the vaccinees in the 1/5- and 1/10-dose arms, respectively, were responders, versus 94% in the full-dose arm; for serogroup A, 92% and 88% were responders, respectively, versus 95%. Non-inferiority was demonstrated between the full dose and both fractional doses in SBA seroresponse against serogroups W135 and Y, in total population analysis. Non-inferiority was shown between the full and 1/5 doses for serogroup A in the population non-immune prior to vaccination. Non-inferiority was not shown for any of the fractionate doses for serogroup C. Safety and tolerability data were favourable, as observed in other studies. Conclusions While the advent of conjugate A vaccine is anticipated to largely contribute to control serogroup A outbreaks in Africa, the scale-up of its production will not cover the entire “Meningitis Belt” target population for at least the next 3 to 5 years. In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns. Trial Registration ClinicalTrials.gov NCT00271479
References
[1]
Lapeyssonnie L (1968) [Comparative epidemiologic study of meningococcic cerebrospinal meningitis in temperate regions and in the meningitis belt in Africa. Attempt at synthesis]. Med Trop 28: 709–720.
[2]
World Health Organization (2000) Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec 75: 306–309.
[3]
Ouedraogo-Traore R, Hoiby EA, Sanou I, Sangare L, Kyelem N, et al. (2002) Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand J Infect Dis 34: 804–807. doi: 10.1080/0036554021000026949
[4]
World Health Organization (2002) Meningococcal disease, serogroup W135, Burkina Faso. Wkly Epidemiol Rec 77: 152–155.
[5]
Zombre S, Hacen MM, Ouango G, Sanou S, Adamou Y, et al. (2007) The outbreak of meningitis due to Neisseria meningitidis W135 in 2003 in Burkina Faso and the national response: main lessons learnt. Vaccine 25: Suppl 1A69–A71. doi: 10.1016/j.vaccine.2007.04.044
[6]
World Health Organization (2007) Risk of epidemic meningitis in Africa: a cause for concern. Wkly Epidemiol Rec 82: 79–87.
[7]
Greenwood B (2006) Editorial: 100 years of epidemic meningitis in West Africa-has anything changed? Trop Med Int Health 11: 773–780. doi: 10.1111/j.1365-3156.2006.01639.x
[8]
Jodar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359: 1499–1508. doi: 10.1016/S0140-6736(02)08416-7
Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Branche WC Jr, et al. (1970) Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis 121: 372–377. doi: 10.1093/infdis/121.4.372
[11]
Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC (1975) Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 56: 1536–1547. doi: 10.1172/JCI108235
[12]
Griffiss JM, Brandt BL, Broud DD (1982) Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 37: 205–208.
[13]
Griffiss JM, Brandt BL, Broud DD, Altieri PL, Berman SL (1985) Relationship of dose to the reactogenicity and immunogenicity of meningococcal polysaccharide vaccines in adults. Mil Med 150: 529–533.
[14]
Brandt BL, Griffiss JM, Broud DD, Boslego JW, Kluwer Academic Publishers, editors (1988) Tetravalent meningococcal polysaccharide vaccine. Relashionship of dose to immunogenicity and reactogenicity in young adults. Gonococci and Meningococci. Dordrecht, The Netherlands: pp. 33–37.
[15]
Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, et al. (1999) Epidemiology of bacterial meningitis in Niamey, Niger, 1981–96. Bull World Health Organ 77: 499–508.
[16]
Lellouch J, Lazar P (1974) Méthodes statistiques en expérimentation biologique. Paris, Flammarion.
[17]
Borrow R, Carlone GM (2001) Serogroup B and C serum bactericidal assays. In: Pollard AJ MMe, editor. Meningococcal vaccines: methods and protocols. Methods in molecular medicine. Totowa (New Jersey): Humana Press. pp. 289–304.
[18]
Carlone GM, Frasch CE, Siber GR, Quataert S, Gheesling LL, et al. (1992) Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol 30: 154–159.
[19]
Joseph H, Balmer P, Bybel M, Papa T, Ryall R, et al. (2004) Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol 11: 1–5. doi: 10.1128/CDLI.11.1.1-5.2004
[20]
Caugant DA, Fogg C, Bajunirwe F, Piola P, Twesigye R, et al. (2006) Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. Trans R Soc Trop Med Hyg 100: 1159–1163. doi: 10.1016/j.trstmh.2006.01.004
[21]
Andrews N, Borrow R, Miller E (2003) Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10: 780–786. doi: 10.1128/cdli.10.5.780-786.2003
[22]
Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129: 1307–1326. doi: 10.1084/jem.129.6.1307
Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 23: 2222–2227. doi: 10.1016/j.vaccine.2005.01.051
[25]
Jodar L, Stephens D, Feavers IM (2002) Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay. Biologicals 30: 323–329.
[26]
Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH (1980) Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis 142: 861–868. doi: 10.1093/infdis/142.6.861
[27]
Gold R, Artenstein MS (1971) Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ 45: 279–282.
[28]
Yergeau A, Alain L, Pless R, Robert Y (1996) Adverse events temporally associated with meningococcal vaccines. CMAJ 154: 503–507.
[29]
Patel M, Lee CK (2005) Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev CD001093:
[30]
Joint United Nations Programme on HIV/AIDS (2008) Country situation analysis, Uganda. Available: http://www.unaids.org/en/CountryResponse？s/Countries/Uganda.asp. Accessed 11 January 2008.
[31]
Meningococcal disease, Great Lakes area (Burundi, Rwanda, United Republic of Tanzania)—update (2002) Wkly Epidemiol Rec 77: 317.
[32]
Obaro SK, Ota MO (2006) Sense and the science of childhood immunization: can we achieve more with less? Vaccine 24: 6460–6467. doi: 10.1016/j.vaccine.2006.06.051
